EDX Medical Group plc (AIM: EDX), the Cambridge-based digital diagnostics company focused on early disease detection, has appointed Dr Joanne Hackett and Mr Peter Collins as non-executive directors with immediate effect. Both appointees bring extensive commercial and strategic experience across the diagnostics and life sciences sectors. The announcement signals EDX Medical's intent to strengthen its board ahead of further commercialisation of its diagnostic products and services portfolio.

Key Points

  • EDX Medical Group plc (AIM: EDX) is a Cambridge-based developer and supplier of digital diagnostic products and services
  • Dr Joanne Hackett and Mr Peter Collins appointed as non-executive directors with immediate effect on 11 November 2026
  • Neither appointee holds ordinary shares in the Company at the time of appointment
  • Investors may watch for how the new board appointments support EDX Medical's commercialisation strategy and partnership development

Dr Joanne Hackett Joins EDX Medical Board with Global Healthcare Commercialisation Experience

Dr Joanne Hackett, aged 47, currently serves as Vice President and Global Head of Health System Services at IQVIA, a leading provider of clinical research services and commercial insights to the life sciences and healthcare industries. Her previous roles include chief commercial officer at Genomics England, chief commercial officer and interim chief executive at the Precision Medicine Catapult, director of commercial development at UCL Partners, and strategy lead at Pfizer Neusentis. The announcement states she brings global experience across academic, business, and clinical institutions, a background the board considers directly relevant to EDX Medical's growth ambitions in diagnostics.

Peter Collins Brings Precision Oncology and Liquid Biopsy Track Record to the EDX Medical Board

Mr Peter Collins, aged 67, is described in the announcement as a precision oncology and molecular diagnostics executive with a track record of commercialising breakthrough technologies across companion diagnostics, liquid biopsy, and molecular residual disease. He has held senior leadership roles at DxS, GSK, Guardant Health, Inivata, and SAGA Diagnostics. The disclosure indicates his expertise spans business development, commercial strategy, market access, strategic partnerships, and company building, with a focus on translating scientific innovation into clinically adopted, reimbursed, and scalable products — areas central to EDX Medical's own operating model.

EDX Medical's Cambridge Operations and Strategic Partnerships Provide the Context for Board Expansion

EDX Medical Group operates its own facilities in Cambridge, UK, and holds strategic product and technology partnerships with organisations including Thermo Fisher EMEA Ltd. The company was founded by Professor Sir Christopher Evans, OBE, alongside chief executive Dr Mike Hudson, and provides doctors, hospitals, and insurers with access to a portfolio of clinical diagnostics products and services. Chairman Dr Mike Owen noted in the announcement that the two appointments bring "a wealth of experience which will serve the Company well," while Professor Sir Chris Evans highlighted their skills in commercialising companies as a "huge asset" to the Group's continued development.